Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. - Wikidata - awgldk - TriplyDB

Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.

Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.

http://www.wikidata.org/entity/Q34066011

about

Orthopoxvirus genes that mediate disease virulence and host tropism The origin of the variola virus Complement and its role in protection and pathogenesis of flavivirus infections A survey of host range genes in poxvirus genomes Why has Not There been More Research of Concern?Prediction of steps in the evolution of variola virus host range Poxviruses and the evolution of host range and virulence Dual-use research and technological diffusion: reconsidering the bioterrorism threat spectrum.Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins.An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus.Surviving mousepox infection requires the complement system Complement evasion by human pathogens.Antagonism of the complement component C4 by flavivirus nonstructural protein NS1.Complement Evasion Strategies of Viruses: An Overview.Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity Microbial subversion of the immune response.Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.Complement and viral pathogenesis Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Genetic engineering and biological weapons. New technologies, desires and threats from biological research.Elucidating the role of the complement control protein in monkeypox pathogenicity Advances in life sciences and bioterrorism. Risks, perspectives and responsibilities.Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus Macroevolutionary Immunology: A Role for Immunity in the Diversification of Animal life.Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons.Openness versus Secrecy in Scientific Research Abstract.Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics.The Vaccinia virus complement control protein modulates adaptive immune responses during infection Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.Pathogen security-help or hindrance?Poxvirus immunomodulatory strategies: current perspectives Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.A new synthesis for dual use research of concern.Dual-Use Review and the IRB.Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes.The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins The evolution of immune mechanisms.Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation.

P2860

Q21285044-50AD8D1C-D4FB-4E17-A231-6B1D7A245B5D Q26863252-EFB8077C-077C-466E-82B8-5AE4269337B4 Q27490236-B8D76072-2F5B-4BDD-BD77-64E7936D0DAA Q28389388-C14C2925-0D85-4DE0-8060-301C56DBF384 Q28655459-023F5BDF-F470-4ABD-AFF4-B435BC293EEC Q28657815-563B9A06-F739-470F-B46D-854619FB3B38 Q28658130-BF4A11A2-8262-4054-A5D7-6A6A28C6C6A3 Q30089796-6489FE5E-7D55-4EBE-BB28-FAE9EE847937 Q30453052-C858FCEE-718B-465B-B0B9-E7B013E3D2FE Q31121628-33C7690A-A4A1-44FA-8AB0-6F7F56FCA905 Q33396210-342AA889-9236-4039-9E3C-20A81AB6E385 Q33623972-3356F4D7-DC99-465E-9F50-F56F5427DB96 Q33795001-92838E08-93BA-4541-97CE-47987189E152 Q33804431-6E51C4BC-F431-4FCE-82FC-21E1154CD7D4 Q33972574-49914E0E-0807-4D18-B7EC-CE5187FA859B Q34064310-5C1098EC-73CD-4E1E-A818-2116DEB8BADE Q34069057-4F351326-6D1C-4DDF-87A2-971FB1280DC4 Q34120177-AD6D098A-8F94-4BF5-BC2A-6E994191323B Q34162421-0BBA32E7-6DF4-4857-828B-6887CB78708B Q34190609-93896BAB-D547-43F0-97CB-A9AF19A533AA Q34203461-E2691690-2B3B-4E1E-ADE8-3C4AD0220F25 Q34230482-A8E81C12-B434-4737-A216-5917C19DEEEB Q34250677-42232546-4CFE-4E8C-A0E8-8688465B615B Q34260704-954BBFAA-38C8-4FA1-9807-BC86271C5D0E Q34261452-F9F6A079-3F9D-4E34-A675-421CD7213737 Q34328870-38A84676-B4EB-40C3-94F1-190304780DCB Q34346923-E5004EDF-3C45-4485-BFD8-DB20E7E3BBD1 Q34524562-ED5C472F-8373-4700-8236-DE6136BCC0CD Q34742926-1EDEB30A-08C4-4D28-9742-D00E73F3B535 Q34829635-9996D14B-665D-4454-842F-E47E43CBF954 Q34841901-4D8ECBD2-768A-46D1-B0CD-E14FDC23F61C Q35125981-2763AA6F-974B-4577-AFD3-608460C1729C Q35155228-49848AFF-B27B-4514-850D-B9A7148C2976 Q35367093-0368AFFD-8878-496A-9C40-8AA25670ED60 Q35416787-074EEF3D-92A9-4F05-87BC-5FACB58D520D Q35676435-423840D5-9639-4007-82DD-83524292215D Q35827465-F6C57742-942C-46E5-812E-EDC7144650C4 Q35963805-16668072-D2E1-481A-B2DA-64DC7EA86F34 Q36451080-6620F0F3-82B9-4F50-8B31-609682CA077D Q36498115-A907B9FF-EFE5-4A35-AF86-45ACB8244F15

P2860

Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.

http://www.wikidata.org/entity/Q34066011

description

2002 nî lūn-bûn

@nan

2002 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Variola virus immune evasion d ...... inhibitor of human complement.

@ast

Variola virus immune evasion d ...... inhibitor of human complement.

@en

Variola virus immune evasion d ...... inhibitor of human complement.

@nl

type

label

Variola virus immune evasion d ...... inhibitor of human complement.

@ast

Variola virus immune evasion d ...... inhibitor of human complement.

@en

Variola virus immune evasion d ...... inhibitor of human complement.

@nl

prefLabel

Variola virus immune evasion d ...... inhibitor of human complement.

@ast

Variola virus immune evasion d ...... inhibitor of human complement.

@en

Variola virus immune evasion d ...... inhibitor of human complement.

@nl

P1433

Q34066011-DF4C750D-2F1C-42B2-87B0-BF0E900A9A97

P1476

Q34066011-2622E875-623B-40BD-9087-3A491D0949CB

P2093

Q34066011-167352CD-E74D-49ED-860B-78265170039B

Q34066011-4976C03F-B420-404D-8E64-C304CC2C2D10

Q34066011-5547E0CF-414B-48DA-BFA8-7D4B32D0C6B2

Q34066011-FB661748-DA6E-4F11-9C76-4C6FE7C46BA1

P2860

Q34066011-0D8EF98B-A7B7-45ED-BA3A-19955C493F30

Q34066011-10A35958-EE76-4466-A9DC-B174356FE7DD

Q34066011-1A623AB3-DFB5-4197-B61B-E0A8D96C265C

Q34066011-25E3BBEB-FE92-4C87-BA96-2E1190B220EC

Q34066011-26AB05FF-C045-4E13-BD9A-DBA4F609198A

Q34066011-29F77AE7-1318-4CC1-BC85-4242355F476A

Q34066011-3EEDC15B-ACF5-4691-A501-72FDD956488C

Q34066011-3FF629B7-3861-4E07-847D-D93717E2B11E

Q34066011-481914AB-A449-43B3-8BED-1DB57E3CDDD6

Q34066011-4A673B52-7BDE-4383-9176-78E5C6E6284A

P304

Q34066011-D7AC923D-FBE5-47F8-B55B-D4F3AC18C986

P31

Q34066011-8AA65C83-2078-4FBD-BEDA-9BBF3DF42030

P356

Q34066011-A3A20602-D23C-4830-A5DF-3C02B1C86266

P407

Q34066011-35B61785-E6A5-40F0-BC79-B17105D001C6

P433

Q34066011-77B69BE0-20F9-40E7-A2E8-6F8CD2920D9D

P478

Q34066011-B5ED0BDD-5907-4ABE-A078-7EC1CC96453D

P577

Q34066011-0F6621B3-463A-404F-BB08-884DE82647CC

P5875

Q34066011-F4B50274-3647-4B56-8768-D3D6C5DAF554

P698

Q34066011-EFAC2349-C643-4FF8-981A-C4AE533A967D

P932

Q34066011-09554C46-5BC8-44EE-ABD4-61508A94FACD

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Variola virus immune evasion d ...... inhibitor of human complement.

@en

P2093

Ariella M Rosengard

http://www.w3.org/2001/XMLSchema#string

Robert Jimenez

http://www.w3.org/2001/XMLSchema#string

Yu Liu

http://www.w3.org/2001/XMLSchema#string

Zhiping Nie

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis

Complement receptor is an inhibitor of the complement cascade

Poxvirus pathogenesis

Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution

Crystal structure of two CD46 domains reveals an extended measles virus-binding surface

Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans

Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins

Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane

Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity

Sites within the complement C3b/C4b receptor important for the specificity of ligand binding.

P304

8808-8813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.112220499

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2002-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11337494

http://www.w3.org/2001/XMLSchema#string

P698

12034872

http://www.w3.org/2001/XMLSchema#string

P932

124380

http://www.w3.org/2001/XMLSchema#string